These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 1421050)

  • 1. Comparative bioavailability and steady state fluctuations of Tegretol commercial and carbamazepine OROS tablets in adult and pediatric epileptic patients.
    Thakker KM; Mangat S; Garnett WR; Levy RH; Kochak GM
    Biopharm Drug Dispos; 1992 Nov; 13(8):559-69. PubMed ID: 1421050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative study of bioavailability and clinical efficacy of carbamazepine in epileptic patients.
    Silpakit O; Amornpichetkoon M; Kaojarern S
    Ann Pharmacother; 1997 May; 31(5):548-52. PubMed ID: 9161646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative bioavailability of carbamazepine from two slow-release preparations.
    Reunanen M; Heinonen EH; Nyman L; Anttila M
    Epilepsy Res; 1992 Mar; 11(1):61-6. PubMed ID: 1563339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Double-blind crossover comparison of Tegretol-XR and Tegretol in patients with epilepsy. The Tegretol OROS Osmotic Release Delivery System Study Group.
    Neurology; 1995 Sep; 45(9):1703-7. PubMed ID: 7675230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dissolution and relative bioavailability of two carbamazepine preparations for children with epilepsy.
    Hartley R; Aleksandrowicz J; Bowmer CJ; Cawood A; Forsythe WI
    J Pharm Pharmacol; 1991 Feb; 43(2):117-9. PubMed ID: 1672895
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparative pharmacokinetic study of conventional and chewable carbamazepine in epileptic patients.
    Patsalos PN
    Br J Clin Pharmacol; 1990 May; 29(5):574-7. PubMed ID: 2350535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Double dummy comparison between once and twice daily dosing with modified-release carbamazepine in epileptic patients.
    McKee PJ; Blacklaw J; Carswell A; Gillham RA; Brodie MJ
    Br J Clin Pharmacol; 1993 Sep; 36(3):257-61. PubMed ID: 9114913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative bioavailability study of a conventional and two controlled release oral formulations of Tegretol (carbamazepine)--200 mg.
    Revankar SN; Bhatt AD; Desai ND; Bolar HV; Sane SP; Tipnis HP
    J Assoc Physicians India; 1999 Sep; 47(9):886-9. PubMed ID: 10778658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Evaluation of the biological availability of 2 carbamazepine preparations].
    Niedzielska K; Rosnowska M; Kuran W
    Neurol Neurochir Pol; 1986; 20(5):415-20. PubMed ID: 3295573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiple-dose pharmacokinetic study with a slow-release carbamazepine preparation.
    Reunanen M; Heinonen E; Anttila M; Järvensivu P; Lehto H; Hokkanen E
    Epilepsy Res; 1990 Jul; 6(2):126-33. PubMed ID: 2387286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A practical study of the efficacy of a delayed-action preparation of carbamazepine (Tegretol CR 400) in the treatment of patients with partial epilepsy ].
    Vojvodić NM; Sokić DV; Janković SM; Lević Z
    Srp Arh Celok Lek; 2002; 130(1-2):19-26. PubMed ID: 12073283
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic comparison of two carbamazepine slow-release formulations.
    Jensen PK; Møller A; Gram L; Jensen NO; Dam M
    Acta Neurol Scand; 1990 Aug; 82(2):135-7. PubMed ID: 2256443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative bioavailability of two carbamazepine tablets.
    Glende M; Hüller H; Mai I; Migulla H; Prümke J; Schumann G
    Int J Clin Pharmacol Ther Toxicol; 1983 Dec; 21(12):631-3. PubMed ID: 6668101
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population pharmacokinetics of steady-state carbamazepine in Egyptian epilepsy patients.
    El Desoky ES; Sabarinath SN; Hamdi MM; Bewernitz M; Derendorf H
    J Clin Pharm Ther; 2012 Jun; 37(3):352-5. PubMed ID: 21883329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monotherapy with conventional and controlled-release carbamazepine: a double-blind, double-dummy comparison in epileptic patients.
    McKee PJ; Blacklaw J; Butler E; Gillham RA; Brodie MJ
    Br J Clin Pharmacol; 1991 Jul; 32(1):99-104. PubMed ID: 1888646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Formulation, release characteristics and bioavailability study of oral monolithic matrix tablets containing carbamazepine.
    Barakat NS; Elbagory IM; Almurshedi AS
    AAPS PharmSciTech; 2008; 9(3):931-8. PubMed ID: 18686038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of absorption rate and bioavailability of two brands of carbamazepine.
    Revankar SN; Desai ND; Bhatt AD; Bolar HV; Sane SP; Gupta C; Kamat DV
    J Assoc Physicians India; 1999 Jul; 47(7):699-702. PubMed ID: 10778590
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Daily fluctuation of plasma levels with conventional and controlled-release carbamazepine: correlation with adverse effects.
    Bareggi SR; Tata MR; Guizzaro A; Pirola R; Parisi A; Monza CG
    Int Clin Psychopharmacol; 1994; 9(1):9-16. PubMed ID: 8195585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bioavailability of two carbamazepine preparations during chronic administration to epileptic patients.
    Morselli PL; Monaco F; Gerna M; Recchia M; Riccio A
    Epilepsia; 1975 Dec; 16(5):759-64. PubMed ID: 1222752
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical development of an everolimus pediatric formulation: relative bioavailability, food effect, and steady-state pharmacokinetics.
    Kovarik JM; Noe A; Berthier S; McMahon L; Langholff WK; Marion AS; Hoyer PF; Ettenger R; Rordorf C
    J Clin Pharmacol; 2003 Feb; 43(2):141-7. PubMed ID: 12616666
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.